Bristol-Myers Squibb
Additional savings at Bristol Myers Squibb
Bristol Myers Squibb is preparing for upcoming patent expirations for Eliquis, Opdivo and Revlimid, where the European patent has already expired. In response...
Billions rain over Swedish health fund after Big Pharma purchase
The news of AstraZeneca's acquisition of Fusion Pharmaceuticals for...
Iconovo begins 2024 with orders from leading pharmaceutical companies
Iconovo has received an order from one of...
Oncoinvent's CEO: "Radiopharmaceuticals have emerged as the hottest area in oncology"
Radiopharmaceuticals is a hot and growing area that...
News roundup Tuesday, December 19
The latest from BioStock
Saniona made further progress in Q3
Saniona's Q3 report summarizes a period of increased activity...
News roundup Friday, July 7
FDA
News roundup Thursday, April 27
Alzinova
Covid-19 products face tougher future
News roundup Wednesday, January 18
The latest from BioStock
News roundup Tuesday, January 17
The latest from BioStock
Fewer approvals in 2022 from cautious FDA
After approving an average of 51 drugs...
Notes
iZafe takes the next step in the Nordics – begins Finnish partnership for Dosell
Senzime's partner receives FDA approval for TetraGraph module
Ellen sells the business for SEK 13,3 million
Oncopeptides increases sales in the second quarter
Alvotech acquires Ivers-Lee Group in Switzerland
NEWSLETTER
NEWS
Merck gears up in lung diseases with giant acquisition
AstraZeneca strengthens gene therapy portfolio with deals worth up to $825 million
AlzeCure Pharma: “We have good momentum”
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The EU's new life science strategy – a step in the right direction or just fluff?
Early signs of spring in an otherwise frosty biotech landscape
